Skip to main content
LUYE PHARMA GROUP LTD. logo

LUYE PHARMA GROUP LTD. — Investor Relations & Filings

Ticker · 1M4B ISIN · XS2927538962 SGX Manufacturing
Open in API
Filings indexed 5 across all filing types
Latest filing 2025-09-10 Capital/Financing Update
Country SG Singapore
Listing SGX 1M4B

About LUYE PHARMA GROUP LTD.

https://www.luye.cn/lvye_en/

LUYE PHARMA GROUP LTD. is an international pharmaceutical company dedicated to the research, development, manufacturing, and sale of innovative medications. The company focuses on therapeutic areas including the central nervous system, oncology, and cardiovascular diseases, alongside orthopaedics, neurology, and gastroenterology. Its product portfolio, comprising over 50 products, addresses various medical conditions such as schizophrenia, depression, and cancer. A key strength lies in its expertise in high-barrier delivery systems like microspheres and liposomes. With global R&D centers, Luye Pharma is actively advancing its pipeline, including novel molecular entities like LY03015 and LY03017 for conditions such as Alzheimer’s Disease-related Psychosis, and has achieved approvals for products like Rykindo® (LY03004) in major markets. Its business operations extend across more than 80 countries and regions worldwide.

Recent filings

Filing Released Lang Actions
Bondholder's Early Redemption (Put Option)::Voluntary
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion of convertible bonds by Luye Pharma Group Ltd. It details the conversion of Tranche A and Tranche B bonds into shares, the resulting share capital changes, and the delisting of the Tranche A Bonds from the SGX-ST. The content focuses on financing activities, specifically bond conversion and capital structure changes. The document length is 2969 characters, which is relatively short and typical for a capital/financing update announcement. There is no indication that this is a full financial report, audit, or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2025-09-10 English
Bondholder's Early Redemption (Put Option)::Voluntary
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the conversion of convertible bonds into shares by Luye Pharma Group Ltd. It references previous announcements and details the allotment of shares following the bond conversion. The document is only 2197 characters long and does not contain financial statements or detailed financial analysis. It is an update on capital structure changes due to bond conversion, which fits the category of Capital/Financing Update (CAP).
2025-09-09 English
Bondholder's Early Redemption (Put Option)::Voluntary
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the conversion of convertible bonds into shares by Luye Pharma Group Ltd. It references previous announcements and details the allotment of shares following the bond conversion. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is primarily an update on a capital structure event (conversion of bonds to shares). Given the short length (2175 characters) and the nature of the content, it fits best under Capital/Financing Update (CAP).
2025-08-20 English
Bondholder's Early Redemption (Put Option)::Voluntary
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the conversion of convertible bonds into shares by Luye Pharma Group Ltd. It details the conversion notice, the number of shares allotted, and the updated share capital and bond principal amounts. There is no financial statement, detailed financial analysis, or comprehensive report content. The document is an update on a capital structure event (conversion of bonds to shares), which fits the category of Capital/Financing Update (CAP). The document length is short (2154 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2025-08-14 English
Bondholder's Early Redemption (Put Option)::Voluntary
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion of convertible bonds into shares by Luye Pharma Group Ltd. It details the conversion notice, the number of shares allotted, the conversion price, and the resulting changes in share capital and bond principal amount. There is no financial report, earnings data, or management discussion. The content focuses on a capital structure change due to bond conversion, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-08-01 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.